Therapy Areas: Cardiovascular
Myovant Sciences names new chief commercial officer
8 November 2018 - Myovant Sciences Ltd (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for women's health and endocrine dis...
AstraZeneca divests rights of Alvesco, Omnaris and Zetonna to Covis Pharma
7 November 2018 - AstraZeneca plc (LSE:AZN), a global, science-led biopharmaceutical company, announced on Tuesday that it has entered into an agreement with Covis Pharma B.V (Covis Pharma), a special...
Real-World Evidence Study Shows Empagliflozin Reduces Risk for Hospitalisation for Heart Failure
5 November 2018 - - Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in ...
Acesion Pharma reports positive results from Phase 1 clinical trial of lead compound in cardioversion, AP30663
5 November 2018 - Danish biotech company Acesion Pharma, a developer of novel treatments for atrial fibrillation (AF), on Monday declared positive results from the Phase 1 clinical trial of AP30663, a...
Omeicos Therapeutics Closes EUR 17m Series C Financing to Advance Lead Candidate OMT-28 Towards Pivotal Trials in Atrial Fibrillation
2 November 2018 - - German biopharmaceutical company Omeicos Therapeutics has closed a EUR 17m (approx. 19.5m) Series C financing led by new investor Forbion, the company said.

Existing i...
BioCardia, CellProThera Partner for Clinical Trial and Marketing in Singapore of Early Stem Cell Therapy for Patients Following Myocardial Infarction
2 November 2018 - - France-based cell therapy product developer CellProThera and US-based regenerative biologic therapies developer BioCardia (OTC: BCDA) have inked an agreement to expand their c...
Related Headlines

AstraZeneca signs agreement to divest rights to Nexium in Europe and Vimovo worldwide (ex-US) to Grünenthal

Eli Lilly signs global licensing and research collaboration with Dicerna Pharmaceuticals

Lancet Publishes Pivotal Trial Results for Shionogi's Cefiderocol

Dicerna Presents Late-Breaking Data Supporting Use of DCR-PHXC in Adults with Primary Hyperoxaluria Types 1 and 2 (PH1 and PH2)

Nuvelution Pharma Appoints Ways as Chief Medical Officer

Alexion and Dicerna Forge Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases

Cipher Pharmaceuticals introduces Brinavess in Canada

Phase III Lonsurf Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer, According to Servier and Taiho Oncology

AstraZeneca and Merck announce Lynparza trial shows 70% reduction in PFS ovarian cancer

Valbiotis Confirms Interest in the Study of the Intestinal Microbiota

New Guidance from ADA and EASD Recommends Use of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Patients with Type 2 Diabetes

Transseptal Solutions passes the US FDA's 510(k) clearance for the TSP Crosser Transseptal Access System for transcatheter left atrium procedures

Neovasc awarded US FDA's breakthrough device designation for the Neovasc Reducer

PTC Therapeutics Presents Initial Data from Patient Registry Demonstrating Translarna Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation

New Consensus Report from The American Diabetes Association and the European Association for the Study of Diabetes Calls for Paradigm Shift to Patient-Centered Care for Type 2 Diabetes